Buspirone


Generic Medicine Info
Administration
May be taken with or without food. Take consistently either always w/ or always w/o meals.
Contraindications
Epilepsy. Concomitant use w/ MAOIs. Severe renal (CrCl <20mL/min) or hepatic impairment. Lactation.
Special Precautions
Patient w/ acute narrow-angle glaucoma, myasthenia gravis, drug dependence. Renal or hepatic impairment. Patient Counselling This drug may cause sedation and dizziness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor mental status.
Adverse Reactions
Nervousness, insomnia, disturbance in attention, depression, confusion, seizure, sleep disorder; dizziness, headache, light-headedness, excitement, somnolence, paraesthesia, blurred vision, coordination disorder, tremor, tinnitus; tachycardia, palpitation, chest pain; nasal congestion, pharyngolaryngeal pain; nausea, abdominal pain, dry mouth, diarrhoea, constipation, vomiting; cold sweat, rash, musculoskeletal pain, fatigue. Rarely, angioneurotic oedema, ecchymosis, urticaria.
Drug Interactions
Increased serum concentration when used w/ CYP3A4 enzyme inhibitors (e.g. erythromycin, itraconazole, nefazodone, ritonavir, diltiazem, verapamil). Decreased metabolism and therapeutic effect when used w/ CYP3A4 enzyme inducers (e.g. rifampicin). Enhanced sedative effect w/ baclofen, lofexidine, nabilone, antihistamines. May increase serum concentration of haloperidol. Buspirone does not exhibit cross-tolerance w/ sedative/hypnotics (e.g. benzodiazepine) and will not block symptoms of their withdrawal, gradually withdraw such agents prior to initiation of buspirone.
CIMS Class
Anxiolytics
ATC Classification
N05BE01 - buspirone ; Belongs to the class of azaspirodecanedione derivatives anxiolytics. Used in the management of anxiety, agitation or tension.
Disclaimer: This information is independently developed by CIMS based on buspirone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in